Chronic kidney disease (CKD) is a highly prevalent condition that contributes to a substantial proportion of disease burden globally and continues to rise in rank among leading causes of death (Bikbov et al., 2020). In 2017, almost 700 million cases of all-stage CKD were recorded, with a global prevalence of 9.1% (Bikbov et al., 2020). The prevalence of end-stage renal disease (ESRD), the final stage of CKD, was also found to be increasing annually, especially in developing countries (Ghimire et al., 2021).ESRD is a distressing disease characterized with irreversible impairments in kidney function and required long-term dialysis therapy. As the most commonly used and important renal replacement therapy (Robinson et al., 2016), maintenance haemodialysis (MHD) is vital for patients with ESRD to filter out excess hydrate and metabolic waste. However, due to the pressure of long-term therapy and